This inventor holds 1 USPTO granted patent. Top assignee: Instytut Farmaceutyczny. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Wioleta Maruszak: Innovator in Pharmaceutical Chemistry
Introduction
Wioleta Maruszak is a prominent inventor based in Warsaw, Poland. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic use. Her work has led to the creation of innovative solutions that enhance the efficacy of existing medications.
Latest Patents
Wioleta holds 1 patent for her invention titled "Crystalline polymorphs of methanesulfonic acid addition salts of Imatinib." This invention pertains to the methanesulfonic acid addition salts of Imatinib and their synthesis. Specifically, it focuses on the synthesis of the crystalline α-form of Imatinib methanesulfonate. Additionally, the invention introduces a novel acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide with two molecules of methanesulfonic acid, along with its polymorphic forms and pharmaceutical compositions.
Career Highlights
Wioleta is affiliated with the Instytut Farmaceutyczny, where she continues to advance her research in pharmaceutical sciences. Her dedication to innovation has positioned her as a key figure in her field, contributing to the development of new therapeutic agents.
Collaborations
Wioleta collaborates with esteemed colleagues, including Bogdan Zagrodzki and Dorota Samson-Lazinska. These partnerships enhance her research efforts and foster a collaborative environment for innovation.
Conclusion
Wioleta Maruszak's contributions to pharmaceutical chemistry exemplify the impact of innovative research on healthcare. Her work not only advances scientific knowledge but also holds the potential to improve patient outcomes through new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile